Artivion, Inc. (NYSE:AORT) Receives Average Recommendation of “Buy” from Analysts

Shares of Artivion, Inc. (NYSE:AORT) have received an average rating of “Buy” from the seven brokerages that are presently covering the stock, Marketbeat.com reports. Six investment analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. The average 1-year target price among brokers that have issued ratings on the stock in the last year is $32.00.

A number of brokerages have recently commented on AORT. Needham & Company LLC reiterated a “buy” rating and issued a $32.00 target price on shares of Artivion in a report on Tuesday, May 6th. Canaccord Genuity Group began coverage on Artivion in a research report on Tuesday, June 17th. They set a “buy” rating and a $35.00 target price for the company. JMP Securities reissued a “market outperform” rating and issued a $33.00 price target on shares of Artivion in a research report on Tuesday, May 6th. Finally, Citizens Jmp raised Artivion to a “strong-buy” rating in a research report on Tuesday, May 6th.

Insider Buying and Selling at Artivion

In other Artivion news, SVP Marshall S. Stanton sold 10,548 shares of the stock in a transaction that occurred on Friday, May 9th. The stock was sold at an average price of $29.13, for a total transaction of $307,263.24. Following the transaction, the senior vice president now owns 105,332 shares in the company, valued at approximately $3,068,321.16. This represents a 9.10% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, Director Anthony B. Semedo sold 2,600 shares of the stock in a transaction that occurred on Friday, May 23rd. The stock was sold at an average price of $28.47, for a total value of $74,022.00. Following the transaction, the director now owns 33,059 shares in the company, valued at $941,189.73. This represents a 7.29% decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 72,954 shares of company stock worth $2,108,525. 7.60% of the stock is currently owned by insiders.

Institutional Investors Weigh In On Artivion

Several hedge funds and other institutional investors have recently made changes to their positions in AORT. Legacy Advisors LLC acquired a new stake in Artivion during the first quarter worth $28,000. MCF Advisors LLC boosted its holdings in Artivion by 109.3% in the first quarter. MCF Advisors LLC now owns 1,176 shares of the company’s stock valued at $29,000 after purchasing an additional 614 shares during the period. Smartleaf Asset Management LLC boosted its holdings in Artivion by 236.7% in the fourth quarter. Smartleaf Asset Management LLC now owns 1,118 shares of the company’s stock valued at $32,000 after purchasing an additional 786 shares during the period. Point72 Asia Singapore Pte. Ltd. purchased a new stake in Artivion during the 4th quarter worth about $64,000. Finally, KLP Kapitalforvaltning AS purchased a new stake in Artivion during the fourth quarter worth approximately $194,000. Institutional investors and hedge funds own 86.37% of the company’s stock.

Artivion Stock Performance

NYSE:AORT opened at $30.58 on Thursday. The stock has a market capitalization of $1.31 billion, a P/E ratio of -61.16 and a beta of 1.62. The stock has a 50-day moving average price of $27.67 and a 200 day moving average price of $27.51. The company has a current ratio of 5.53, a quick ratio of 3.95 and a debt-to-equity ratio of 1.08. Artivion has a 12-month low of $21.97 and a 12-month high of $32.33.

Artivion (NYSE:AORT) last released its quarterly earnings results on Monday, May 5th. The company reported $0.06 earnings per share for the quarter, missing the consensus estimate of $0.12 by ($0.06). The firm had revenue of $98.98 million for the quarter, compared to analysts’ expectations of $94.81 million. Artivion had a negative net margin of 5.49% and a positive return on equity of 3.63%. Equities research analysts forecast that Artivion will post 0.37 EPS for the current fiscal year.

About Artivion

Artivion, Inc manufactures, processes, and distributes medical devices and implantable human tissues worldwide. The company provides BioGlue, a polymer consisting of bovine blood protein and an agent for cross-linking proteins for cardiac, vascular, neurologic, and pulmonary procedures; cardiac preservation services; PhotoFix, a bovine pericardial patch; and aortic arch stent grafts including E-vita Open Plus and E-vita Open Neo.